Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. by Jayson, G. C. & Gallagher, J. T.
British Joumal ofCancer(1997) 75(1), 9-16
© 1997 Cancer Research Campaign
Heparin oligosaccharides: inhibitors of the biological
activity of bFGF on Caco-2 cells
GC Jayson and JT Gallagher
Cancer Research Campaign Department of Medical Oncology, Paterson Institute, Wilmslow Road, Withington, Manchester M20 6BX, UK
Summary A number of growth factors, including members of the fibroblast growth factor (FGF) family - hepatocyte growth factor, vascular
endothelial growth factor and heparin-binding epidermal growth factor - are dependent on heparan sulphate (HS) for biological activity
mediated through their high-affinity signal-transducing receptors. This obligate requirement for HS prompted the search for antagonists of HS
function that could be used as anti-growth factor drugs for the treatment of cancer. Basic FGF (bFGF) was the focus of this study. Caco-2, a
human colon carcinoma cell line, was adapted to growth in serum-free medium so that investigation of its growth factor requirements for
growth and migration could be performed in defined conditions (Jayson GC, Evans GS, Pemberton PW, Lobley RW, Allen T 1994, Cancer
Res, 54, 5718-5723). This cell line multiplied and moved in adose-dependent manner in response to bFGF. Here, we showthatthe mitogenic
response to bFGF is dependent on the presence of heparan sulphate. A library of heparin oligosaccharides with uniform composition but
variable length was generated {general formula [IdoA(2S)-GIcNS(6S)]J, and oligosaccharides of defined lengths were tested for their ability
to inhibit the biological activity of bFGF. While intact heparin and heparin-derived fragments of 12 monosaccharide units did not affect bFGF-
induced cell division or bFGF-induced cell migration, octasaccharides and decasaccharides potently inhibited the bFGF-induced growth and
migration responses. In particular, octasaccharides completely inhibited these biological activities at 10 9g ml-', a clinically achievable and
tolerable concentration. This study shows that the length of an oligosaccharide determines its ability to block the biological activity of bFGF.
The observation that the biological activity of cell-surface heparan sulphate can be antagonized in this way in a human carcinoma cell line
suggests that oligosaccharides should be investigated further as anti-growth factor agents for the treatment of cancer. In addition, the results
suggest that the clinical evaluation of low-molecularweight heparin (LMWH) as an anti-cancer agent might benefitfrom subfractionation ofthe
LMWH, to remove oligosaccharides of 12 or more residues.
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The majority of cancer-related morbidity and mortality in this
country is caused by the growth and metastasis ofadenocarcinoma
(Association of Cancer Physicians, 1994). New treatment strate-
gies are required to improve the prognosis of patients bearing
these cancers, and inhibition of growth factor activity has been
identified as a key approach (Myers et al, 1992; Eisenburger et al,
1993). Since a number of growth factors that are involved in
cancer cell growth and angiogenesis (Mustonen and Alitalo, 1995)
are dependent on heparan sulphate, we have investigated the
potential of heparan sulphate oligosaccharides, which represent
partial growth factor binding sequences, as inhibitors of growth
factor activity.
Heparan sulphate (HS), a glycosaminoglycan (GAG), is a
sulphated polymer of disaccharides that consists of an alternate
arrangement of a hexuronic acid [either glucuronic acid or
iduronic acid (IdoA)] and N-acetylated- or N-sulphated-
glucosamine. HS is of particular interest because it contains
domains of highly and poorly sulphated oligosaccharides
(Turnbull and Gallagher, 1991), and the amount of sulphation
differs depending on the cell oforigin. While fibroblasts and aortic
endothelial cells tend to make poorly sulphated HS, hepatocytes
produce highly sulphated HS that resembles heparin in parts
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(Lyon et al, 1994a). HS exists as heparan sulphate proteoglycans
in which it is covalently bound to a protein core and is responsible
forbinding a broad spectrum ofligands, including matrix proteins,
protease inhibitors and growth factors.
Heparan sulphate is found on the surface of nearly all cells in
the body and one of its functions is to act as a co-receptor for a
number of growth factors and chemokines. An enlarging family
of growth factors, including members of the fibroblast growth
factor (FGF) family (Olwin et al, 1992) - vascular endothelial
growth factor (Gitay-Goren et al, 1992), hepatocyte growth factor
(M Lyon, JA Deakin and JT Gallagher, personal communication)
and heparin-binding epidermal growth factor (Higashiyama et al,
1993) - show an obligate requirement for heparan sulphate in
order to activate their high-affinity signal-transducing receptors.
The heparan sulphate co-receptor is necessary for bFGF to
bind (Yayon et al, 1991) and activate (Olwin et al, 1992) its signal-
transducing receptor. The interaction between HS and bFGF is
specific, and a 14-saccharide HS sequence has been identified,
containing an internal sequence offive IdoA(2S)-GlcNS disaccha-
ride units, which bind bFGF with an affinity similar to intact HS.
Oligosaccharides containing fewer copies of this disaccharide
bound bFGF with a reduced affinity (Turmbull et al, 1992). When
the biological activity of similar oligosaccharides was examined,
there were data to suggest that oligosaccharides of eight or fewer
saccharide residues were capable of binding bFGF but would not
support the biological activity of the cytokine, whereas oligosac-
charides of 10 or 12 saccharides both bound and activated bFGF in
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endothelial (Ishihara et al, 1993) and mesenchymal model systems
(Walker et al, 1994). This suggested that short oligosaccharides
were capable ofacting as growth factor inhibitors. However, many
of these studies were carried out in cell-free systems or on HS-
denuded cells in which the oligosaccharide under investigation did
not have to compete with cell-surface or extracellular matrix HS
for the growth factor. Secondly, the composition of oligosaccha-
rides of different lengths was not homogeneous and whether
oligosaccharide length alone (rather than compositional variations)
could determine the inhibitory potential of these molecules
was unknown. To overcome these problems, oligosaccharides of
general formula [IdoA(2S)-GlcNS(6S)]" were generated by chem-
ical scission of bovine lung heparin, and their biological activity
was tested. Each of these disaccharide units contains the sulphate
groups that have been implicated in the binding and activation of
bFGF, namely theN-sulphate on glucosamine and the 2-0-sulphate
on iduronic acid. The 6-0-sulphate is not thought to be important
to the interaction between HS and bFGF (Coltrini et al, 1994;
Ishihara et al, 1994), although ithas been implicated in the interac-
tion between HS and the FGF receptor (Guimond et al, 1993).
The action of HS in the regulation of the growth response of
carcinoma cells to bFGF has notbeen investigated to date. In view
ofthe specificity ofthe interaction between bFGF and HS and the
mandatory role ofHS in bFGF signalling, the apparent HS-medi-
ated activation of the growth factor is a potential target for thera-
peutic control. To investigate these possibilities, we adapted
Caco-2, a human colon carcinoma cell line, to growth in serum-
free, defined conditions. As this cell line responds to bFGF in a
dose-dependent mannerby increasing its rate ofmultiplication and
motility (Jayson et al, 1994), we were able to test the relative
potencies of heparin oligosaccharides of general formula
[IdoA(2S)-GlcNS(6S)]n (where n = 1-6) as inhibitors ofthe mito-
genic and motogenic effects ofbFGF.
MATERIALS AND METHODS
Cell culture
The adaptation of Caco-2 to growth in serum-free conditions and
the materials and methods for measuring the mitogenic and moto-
genic response of Caco-2 to bFGF were outlined in detail in
Jayson et al (1994).
Briefly, Caco-2 was adapted to growth in serum-free conditions
[Dulbecco's modified Eagle medium (DMEM) containing pyru-
vate, glutamine, penicillin and streptomycin with 10 jg ml-' trans-
ferrin (Collaborative Biomedicals) (D+T)] by reducing the serum
concentration at each passage so that the cells eventually grew in
serum-free conditions and underwent differentiation on reaching
confluence, in the same way as the parental cell line.
Determination of the concentration of chlorate needed
to prevent the formation of sulphated GAG
Caco-2 cells were taken at 80% confluence in a T75 flask (Costar)
and incubated for 3 h in sulphate-free DMEM, containing between
0 and 5 mm sodium chlorate, with a 90% and 75% reduction in
cysteine and methionine respectively, and no penicillin or strepto-
mycin. The other constituents of D+T were otherwise the same.
After 3 h, thecells werepassaged into anotherT75 flask containing
the same concentration of sodium chlorate, but also containing
10 ,uCi ml-l [3H]glucosamine (NEN, DuPont) and 10 gCi ml'
Na235SO4 (NEN, DuPont). After 48 h, 1% (v/v) Triton X-100
(Sigma) and 10 mg pronase (Streptomyces griseus, Boehringer
Mannheim) were added to liberate GAG. The sample was filtered
(2 jim filter, Millipore), diluted twice (distilled water, v/v) and
then loaded onto a Mono-Q anion exchange column in a fast
protein liquid chromatographic (FPLC) apparatus (Pharmacia).
Thecolumn was equilibrated with water and a linear gradient up to
2M sodium chloride was used to elute the retained material.
Fractions were collected and their radioactivity determined by
scintillation counting.
The mitogenic response of Caco-2 to bFGF is
dependent on heparan sulphate
Caco-2 at 80% confluence, in 75-cm2 flasks, were incubated for
3 h in 10 mm sodium chlorate in sulphate-free DMEM (Gibco)
containing glutamine, pyruvate and transferrin. Penicillin and
streptomycin were omitted as they contain sulphur, and cysteine
and methionine were reduced to 10% and 25% ofnormal concen-
trations respectively, as they could also provide exogenous
sulphate, which would overcome the effect ofchlorate.
Cells were liberated as a single-cell suspension with trypsin that
was subsequently neutralized with soybean trypsin inhibitor
(Jayson et al, 1994). Approximately 105 cells in 1 ml of chlorate-
containing medium were pipetted into each well ofa 24-well plate
(Costar, flat-bottomed wells). For the first 24 h the cells were
allowed to adhere in the chlorate-containing medium, so that there
were an equal number ofcells in each well.
After 24 h, the medium was changed and growth factors,
glycosaminoglycans and 1 mm magnesium sulphate were added in
various combinations (see Results) to the chlorate-containing
medium. Growth factors and GAGs were used at a concentration
of 10 ng ml-', and the cultures were incubated for 24 h. An aliquot
of 1 jCi of [3H]thymidine (NEN, Dupont) was then added to each
well. Three hours later, the medium containing the radiolabel was
aspirated, and the cells were fixed with ice-cold methanol (BDH)
for 1 h. The cells were treated with at least three washes with ice-
cold 5% trichloroacetic acid (TCA, Sigma) over 18 h to remove
any thymidine that had not been incorporated into DNA. They
were then washedinethanol anddriedin air. The DNA, containing
the thymidine, was dissolved in 0.75 ml of 1 M sodium hydroxide
at 37°C for 3 h, and the completion ofthe solubilization was deter-
mined by light microscopy. The alkali was neutralized with
0.75 ml of 1 M hydrochloric acid and 0.5 ml was mixed with scin-
tillant, and the radioactivity counted on a scintillation counter
(Packard Tricarb 4660, Canberra Packard). To standardize the
findings, the mean radioactivity in the chlorate wells was defined
as 100%. The y-axis shows the percentage increase in DNA
synthesis in excess of that seen in the chlorate wells. The results
are shown (Figure 2) as the mean of at least three experiments
(± s.e.). A linearrelationship between cell numberand [3H] thymi-
dine uptake was established (data not shown).
Analysis of bovine lung heparin (BLH)
A sample of 50 mg of BLH (Sigma) was dissolved in 1 ml of 50
mM Tris (Sigma), 50 mm sodium chloride (BDH), pH 7.8-8 and
exhaustively digested with chondroitinase ABC (EC 4.2.2.4,
Seikagaku, Tokyo, Japan) for 24 h at 370C to remove any contam-
ination with chondroitin or dermatan sulphate. The intact heparin
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was separated from digestion products by anion exchange chro-
matography using a 10 ml DEAE-Sepharose (Sigma) column and
was loaded onto a 1 x 30 cm Sephadex G-50 superfine column
(Pharmacia: fractionation range 500-10 000 MW), pre-equili-
brated with 0.2 M ammonium bicarbonate (BDH) at 20 ml per
hour. The elution position of the heparin was determined by the
measurement of absorption (232 nm), and those fractions
containing the heparin were pooled and exhaustively lyophilized.
The heparin was dissolved in 5 ml of heparinase buffer [0.1 M
sodium acetate (BDH), 0.1 M calcium acetate (BDH), 0.1 mg ml-'
bovine serum albumin (Sigma), pH 7] and exhaustively digested
with heparinase I, II and III (Seikagaku, Tokyo, Japan) at 37°C for
24 h. The degree of digestion was measured by following the
absorption (232 nm) of fractions eluted by gel chromatography
[Biogel P2, (Biorad, Hertfordshire, UK), 1 x 150 cm, 5 ml of0.2 M
ammonium bicarbonate per hour] and was shown to be greater
than 95% (data not shown).
The fractions corresponding to the disaccharides were pooled
and exhaustively lyophilized to remove ammonium bicarbonate.
The disaccharides were dissolved in 1 ml of water and 10 pl were
analysed by strong anion exchange high-performance liquid
chromatography (HPLC) on a Propac PAl analytical column (4 x
250 mm, Dionex, UK). The elution was followed at 232 nm.
Preparation of oligosaccharides from bovine lung
heparin (BLH)
A sample of 50 mg of BLH (Sigma) was treated as above to
remove any contamination with chondroitin or dermatan sulphate.
The oligosaccharides derived from BLH were produced by
the random chemical scission of intact heparin with nitrous
acid, which cleaves heparin at N-sulphated disaccharides. The
lyophilized heparin was dissolved in 1 ml of water and separated
into five aliquots of 200 pl. Nitrous acid was prepared by mixing
0.5 ml of water containing 0.114 g of barium nitrite (Aldrich
Chemical Co.) with 0.5 ml of 0.5 M sulphuric acid and taking the
supematant after (5 min) centrifugation at 13 000 g (Shively and
Conrad, 1976). An aliquot of 50 gl of nitrous acid solution was
added to each aliquot of heparin and the reaction was allowed to
proceed for 5, 10, 15, 20 and 25 s respectively, before it was termi-
nated by the addition of 0.3 ml of 2 M sodium carbonate. The five
aliquots were mixed and the total volume was reduced to less than
1 ml by centrifugal evaporation (Uniscience, Univap). The oligo-
saccharides were separated on a 1.5 x 150 cm Biogel PlO column
(Biorad) pre-equilibrated with 0.2 M ammonium bicarbonate,
running at 8 ml per hour. Aliquots (2 ml) were collected and
the absorption of each was measured at 210 nm using a spectro-
photometer (Cecil 5501 series 5000 spectrophotometer, Cecil,
Cambridge, UK) (Figure 3). Those aliquots containing the hexa-
saccharides (dp6), octasaccharides (dp8), decasaccharides (dplO)
and dodecasaccharides (dpl2) were taken and exhaustively lyo-
philized to remove the ammonium bicarbonate. These were
dissolved in D+T (no transferrin), sterilized by filtration through
0.2 jim filters and used in the assays ofmigration and mitogenesis.
In some experiments, the biological activity of chondroitin
sulphate oligosaccharides was investigated. Chondroitin sulphate
(50 mg, Sigma) was dissolved in chondroitinase buffer (50 mm
Tris, 50 mm sodium chloride, pH 7.8-8) and digested with chon-
droitinase ABC (Proteus vulgaris, EC 4.2.2.4, Seikagaku, Tokyo,
Japan) for 2 h at 37°C. The digested material was then eluted
through the same Biogel PlO column and the absorption (232 nm)
of the eluant was determined. Hexasaccharides and octasaccha-
rides were taken for exhaustive lyophilization and investigation in
the biological assays.
Mitogenic assay
Caco-2 were taken at confluence and liberated as a single-cell
suspension with trypsin. The trypsin was neutralized with soybean
trypsin inhibitor (Sigma) and the cells were resuspended in D+T,
which contained 1 jg ml-' transferrin (Jayson et al, 1994). A
sample of 100 gl containing 104 cells was pipetted into each well
of a 96-well flat-bottomed plate (Costar). After 24 h, the cells had
adhered and the medium was changed to D+T, which did not
contain transferrin. Where appropriate, bFGF (R&D Systems,
USA) was added to give a final concentration of 10 ng ml', and
oligosaccharides were added to produce final concentrations of 1,
10 or 100 jig ml-. The cells were incubated for 4 days and then
fixed in 2% glutaraldehyde (BDH)/Hanks' balanced salt solution
(HBSS) (Gibco) (v/v) for 1 h at room temperature. The cells were
washed and then stained with 0.1% crystal violet (w/v) in 50 mM
sodium tetraborate buffer (pH 9) for 20 min. After washing in
water, the stain was liberated with 100 jil of 10% acetic acid, and
the absorption was measured using an Anthos Labtec (Austria)
plate reader at 540 nm. The influence of the oligosaccharide on
bFGF-induced mitogenesis was calculated by
[(A5,40 ofcells in bFGF +oligosaccharide/A540 ofcontrol cells) -
(A540ofcells inoligosaccharide/A540 ofcontrol cells)] x 100
A linear relationship existed between cell number and uptake of
crystal violet stain (data not shown). The results are presented as
the increase in cell number in the FGF/oligosaccharide-treated
wells compared with that in the wells treated with oligosaccharide
alone. The oligosaccharide concentrations were0, 1, 10 and 100jg
mll.The data are presented as the mean result ofthreeexperiments
(± s.e.) in Figure 5A. The control experiments performed with
chondroitin sulphate oligosaccharides are shown in Figure 5B.
Migration assay
The migration assay involved the measurement of the percentage
ofcells thatmigrated across apolycarbonate membranecontaining
12-jm pores in 24 h in response to bFGF in the presence or
absence ofoligosaccharides.
Caco-2 were taken at confluence, liberated as a single-cell
suspension with trypsin that was then neutralized with soybean
trypsin inhibitor, and the cells were resuspended in D+T (without
transferrin) at 105 cells ml' (Jayson et al, 1994). A sample of 0.5
ml ofcells was pipetted into a well, the base ofwhich was a poly-
carbonate membrane containing 12-jim holes (CostarTranswells).
Aliquots of 0.5 ml of D+T (without transferrin), containing bFGF
at 100 ng ml-' and/or oligosaccharide at0, 10 or 100jm ml' were
added below the membrane. After 24 h, the media above and
below the membrane were aspirated and 1 ml of 2% glutaralde-
hyde/HBSS was added above and below the membrane for at least
1 h at room temperature. The membranes were then washed with
distilled water and stained with 5 jg ml' Hoechst dye (Sigma) for
5 min at room temperature. After two further washes with distilled
water, the membranes were excised, their orientation being main-
tained, and mounted in water on glass slides and examined under a
Zeiss phase-contrast fluorescence microscope. At least 1000 cells
were counted per membrane, and the percentage of cells that had
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Figure 1 Effect of chlorate on [35S]GAG formation. Anion exchange
chromatographs showing the reduction in [3H] glucosamine/[35S]GAG peaks
when Caco-2 cells were incubated in medium containing different
concentrations of sodium chlorate. GAG were eluted from a mono-Q anion
exchange column by a linear sodium chloride gradient (0-2 M). Left axis:
solid line, tritium; fine dotted line, sulphur35. Right axis: linear dotted line,
saline gradient
migrated across the membrane was determined. The results shown
in Figure 6 were calculated by the formula:
% ofcells that migrated in excess ofcontrol =
[(% ofcells migrating in bFGF + oligosaccharide) -
(% ofcells migrating in oligosaccharide)]
Each experiment was repeated three times and the standard errors
calculated. The results are shown in Figure 6.
RESULTS
Figure 1 shows that chlorate was able to reduce the production of
sulphated glycosaminoglycans in a dose-dependent manner. The
graphs show that the glycosaminoglycan (GAG) peak, identified
by its uptake of both [3H]glucosamine and 35S, was reduced by
>95% when the cells were incubated in 5 mm sodium chlorate.
3
0
Figure 2 Effect of heparin and other sulphated GAG on the mitogenic activity
of bFGF. Heparin is required for the mitogenic activity of bFGF. Caco-2 cells
were incubated in 10 mm chlorate for 24 h, passaged into fresh medium
containing FGF, 10 ng ml-1 basic FGF; CS, 10 ng ml-' chondroitin sulphate;
So4, 1 mM magnesium sulphate; EGF, 10 ng ml-' epidermal growth factor.
The data represent the mean ± s.e. for at least three experiments
0
A concentration of 10 mm chlorate was selected for further exper-
iments to guarantee a complete reduction in GAG synthesis.
Caco-2 cells were grown in defined conditions in chlorate-
containing, low-sulphate medium with other additives as shown in
the legend for Figure 2. The data suggest that heparan sulphate is
required for the mitogenic effect ofbFGF on Caco-2. The addition
of heparin to chlorate-treated cells was associated with a minimal
increase (6%) in DNA synthesis in comparison with the back-
ground level observed with chlorate-treated cells. bFGF alone
caused a small stimulation of20% in excess ofcontrol, despite the
treatment of cells with chlorate. However, the addition of bFGF
with heparin caused a 68% increase in DNA synthesis, which was
significantly greater than the sum of bFGF and heparin when
either was given alone, suggesting a strong synergy between the
two and supporting the concept that bFGF is activated by heparin.
Chlorate inhibits the production of sulphated glycosaminogly-
cans by a competitive inhibition of the manufacture of the
physiological sulphate donor, phosphoadenosine phosphosulphate
(Baeuerle and Huttner, 1976; Rapraeger, 1991). However, this
inhibition can be reversed by the exogenous addition of sulphate.
Thus, treatment of the cells with sulphate, despite the presence of
chlorate, was associated with a 30% increase in DNA synthesis,
while incubation of cells in sulphate and bFGF was associated
with a 90% increase in DNA synthesis. The difference between the
sulphate/bFGF and sulphate data points is 60%, a figure that is
similar to the difference between the heparin/bFGF (68% stimula-
tion) and heparin (6% stimulation) data points. Therefore, these
results imply that heparin in solution is equivalent to cell-surface
HS in its ability to promote the activity ofbFGF.
The ability ofchondroitin sulphate (CS) to restore the mitogenic
effect of bFGF was investigated. This showed that CS alone
caused an insignificant increase in DNA synthesis, whereas CS
with bFGF caused 11% stimulation. Since bFGF alone caused
20% stimulation, the addition of CS had no significant effect on
the mitogenic effect of bFGF. This suggests that the mitogenic
activity of bFGF in Caco-2 depends on heparan sulphate, rather
than on other sulphated glycosaminoglycans.
In addition, we investigated the influence ofheparin.on the mito-
genic effect of epidermal growth factor (EGF) in chlorate-treated
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Figure 3 The disaccharide composition of bovine lung heparin. Bovine lung
heparin was completely depolymerized by scission with heparinases 1, 11 and
Ill. Disaccharides were extracted, washed onto a strong anion exchange
column and desorbed by a linear saline gradient. Left axis, A232, solid line;
right axis, linear saline gradient, dotted line
cells. EGF is a non-heparin-binding growth factor and, therefore,
heparin should not increase the mitogenic activity ofEGF. The data
show that EGF alone caused a 41% increase in DNA synthesis
(less than bFGF and heparin), whereas EGF with heparin caused a
55% increase. This minor effect ofheparin is likely to be caused by
an independent action of the polysaccharide since, as indicated
above, heparin does cause a small increase in DNA synthesis in the
absence of exogenous growth factor.
Compositional analysis of bovine lung heparin
Figure 3 shows the composition of bovine lung heparin after
complete depolymerization with heparin lyases (I-III) and separa-
tion of the disaccharides on strong anion exchange HPLC. The
results show that 85% of the disaccharides are the trisulphated
disaccharide IdoA(2S)-GlcNS(6S) and that 95% of all disaccha-
rides contain GlcNS and IdoA(2S), sulphated moieties implicated
in the interaction between bFGF and heparan sulphate (Turnbull et
al, 1992; Ishihara et al, 1994; Maccarana et al, 1993). These data
suggest that oligosaccharides derived from bovine lung heparin
will be quite homogeneous in composition and that the biological
activity of oligosaccharides will result from differences in length
rather than composition.
Preparation of oligosaccharides from bovine lung
heparin
Figure 4 shows the typical absorption (210 nm) profile ofoligosac-
charides, derived by chemical scission of bovine lung heparin,
eluted by Biogel PIO gel filtration chromatography..The column
was precalibrated with radiolabelled oligosaccharides, so that
oligosaccharides of known length could be identified. The dp
labels refer to the degree of polymerization, so that dp6 refers to
hexasaccharides; dp8 to octasaccharides and dpl2 to dode-
casaccharides. Oligosaccharides were separated by taking the
fraction containing the highest amount of an oligosaccharide and
the fractions either side of the main fraction. These were exhaus-
tively lyophilized until there was no further weight loss. Gradient-
polyacrylamide gel electrophoresis (PAGE) analysis showed that
oligosaccharides of a stated length contained at least 90% of that
length ofoligosaccharide (data not shown).
The inhibition of bFGF-induced mitogenesis by
oligosaccharides
Heparin oligosaccharides were added, with or without bFGF, at the
concentrations shown on the x-axis ofFigure 5A. The difference in
cell number between wells that were treated with oligosaccharide
and bFGF and oligosaccharide alone was plotted for each
oligosaccharide at the concentration shown. The results show that
intact heparin and dodecasaccharides do not inhibit bFGF-induced
mitogenesis, even at 100 jg ml-'. On the other hand, hexasaccha-
rides, octasaccharides and decasaccharides inhibited the mitogenic
activity of bFGF at 100 gg ml-'. However, the octasaccharides
also caused a significant reduction in mitogenesis at 10 jig ml-',
whereas neither the hexasaccharides nor the decasaccharides did
this. To investigate the specificity of the effect, the inhibitory
potential of CS hexasaccharides and octasaccharides was investi-
gated. Figure SB shows that these largely had a statistically
insignificant effect on bFGF-induced mitogenesis, suggesting that
a specific class of GAG oligosaccharides was required to inhibit
the biological activity ofbFGF.
The inhibition of bFGF-induced motility by
oligosaccharides
Basic FGF causes a dose-dependent increase in migration (Jayson et
al, 1994). This was demonstrated by counting cells that migrated
across a transwell filter (pore size 12 ,um) over a 24-h period. In the
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Figure 5 The inhibitory activity of sulphated GAG oligosaccharides. (A)
Effect of heparin oligosaccharides on bFGF-induced mitogenesis. (B) Effect
of chondroitin sulphate oligosaccharides on bFGF-induced mitogenesis.*,
hexasaccharides; *, octasaccharides; A, decasaccharides; x,
dodecasaccharides; *, intact heparin. Inset shows dose-response curve for
bFGF-induced Caco-2 mitogenesis. * Significant reduction in the mitogenic
activity of oligosaccharides (P<0.05; Student's two-tailed t-test)
present study, we have used the same assay to study the effects of
oligosaccharide antagonists of bFGF-induced mitogenesis on the
migration response ofcells to this growth factor. The small inset in
Figure 6 shows a typical dose migration curve for Caco-2 cells.
Figure 6 shows thatshortoligosaccharides reducethebFGF-induced
motility ofCaco-2 cells. Octasaccharides were again the most potent
inhibitors of cell motility, as they abolished bFGF-induced cell
migration at 10 jg ml-'. Hexasaccharides caused an insignificant
reduction in motility at 10 jig ml-' but eliminated bFGF-induced
motility at lOOjg ml'. Dodecasaccharides had no effect on cell
motility at 10 jig ml-I butcaused a slight reduction in cell motility at
100 jig ml- that did not achieve statistical significance.
DISCUSSION
The evidence that the mitogenic effect of bFGF is dependent on
HS was derived from mesenchymal models. This is the first
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Figure 6 Effect of heparin-derived oligosaccharides on bFGF-induced cell
motility. Caco-2 cells were pipetted above a membrane containing 12-um
holes and 100 ng ml-' bFGF with oligosaccharides of defined length and the
concentrations shown on the x-axis were added below the membrane. Each
experiment was repeated three times and the mean ± s.e. are shown. *,
hexasaccharides;*, octasaccharides; A, dodecasaccharides. The inset
shows a typical dose-response curve for bFGF-induced Caco-2 migration
through the membrane. * Significant reduction in the mitogenic activity of
oligosaccharides (P<0.05; Student's two-tailed t-test)
demonstration that the mitogenic effect of bFGF in an epithelial
model of cancer is dependent on heparan sulphate (Figure 2). The
data show that heparin, but not chondroitin sulphate, was able to
restore completely the mitogenic effect of bFGF in cells denuded
of functional heparan sulphate. However, the mitogenic effect of
EGF, a non-heparin-binding growth factor, was only slightly
affected by heparin. This suggests that there is a specific require-
ment by bFGF for heparan sulphate rather than an alternative
glycosaminoglycan. This may be mediated either by a synergism
between heparan sulphate receptors and FGF receptors or by
an HS-bFGF-FGF receptor interaction. However, there are no
convincing reports of heparin/heparan sulphate receptors in the
literature. In addition, neitherheparin alone norheparin in the pres-
ence ofEGFincreased DNA synthesis overcontrol levels (chlorate
medium and EGF respectively), supporting the concept that
heparin increases the mitogenic effect ofbFGFby a modulation of
the bFGF-FGF receptor system, rather than through a synergistic
effect mediated through alternative cell-surface receptors.
The depen-dency of bFGF on heparan sulphate, of minimum
length 12-14 saccharides, for its biological activity prompted the
investigation of shorter heparan sulphate oligosaccharides that
represented part of the active site sequences, as growth factor
inhibitors. The ability of oligosaccharides of homogeneous
composition (Figure 3) but variable length (Figure 4) to inhibit
bFGF-induced mitogenesis and motility were examined, and the
data suggest that oligosaccharides of less than ten saccharide
residues inhibit the biological activity of bFGF. Intact heparin
(Figure 2) and dodecasaccharides did not inhibit bFGF-induced
mitogenesis (Figures 2 and 5A) or motility (Figure 6), and chon-
droitin sulphate hexasaccharides and octasaccharides did not
inhibit bFGF-induced mitogenesis, suggesting that there is a
specific inhibitory action of these oligosaccharides. Samples of
100 ,ug ml-' hexasaccharides, octasaccharides and decasaccharides
inhibited both bFGF-induced mitogenesis and motility, whereas
the same concentration of dodecasaccharide (dpl2) did not affect
either parameter.
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It is unlikely that the difference in potency is caused by different
molar concentrations of drug, as the octasaccharides were more
potent inhibitors than the hexasaccharides at the same concentra-
tion (jg ml-'), that is, at a lower molar concentration. Although
both the deca- and hexasaccharides inhibited the mitogenic activity
of bFGF at 100 ,ug ml-', only the octasaccharides were active at
10 jg ml-', aconcentration close to that achieved in patients treated
with low-molecular weight heparin (Bara et al, 1985).
The implication of these data is that the length of a heparan
sulphate oligosaccharide is a critical determinant of its ability to
inhibit growth factor activity and that octasaccharides are very
effective by comparison with dp6 and dplO oligosaccharides. In
addition, the data show that the growth factor-activating potential
of cell-surface and extracellular matrix heparan sulphate can be
overcome by oligosaccharides and that short oligosaccharides are
capable of inhibiting growth factor-induced multiplication and
motility, processes involved in the progression ofcancer.
The results have implications for the biological activity of
commercially available low-molecular weight heparins (LMWHs).
These contain a spectrum of oligosaccharides that range between
tetrasaccharides andhexadecasaccharides (Hirsh andLevine, 1992).
Therefore, the LMWHs are likely to contain certain heparin species
that support the biological activity of bFGF, while others would
inhibit its activity. This suggests that clinical studies ofLMWH, as
anti-growth factor agents, would be more likely to succeed, ifdode-
casaccharides and larger oligosaccharides were removed from
LMWH, a task that is readily achieved by gel filtration.
The mechanism by which heparan sulphate activates bFGF is
unknown, although there are data to suggest that it may act by
inducing conformational changes in bFGF(Prestrelski et al, 1992).
Other data have shown that two bFGF molecules can be bound by
HS, establishing adimer that is required for growth factor receptor
activation (Omitz et al, 1992). In addition, recent publications
have suggested that HS acts as a template by binding to the FGF
receptor as well as to bFGF, thereby bringing bFGF into proximity
with the FGF receptor (Kan et al, 1993). An oligosaccharide could
interfere with any of these processes by occupying HS binding
sites on bFGF, preventing the access offunctional HS to the mole-
cule. Although less sulphated oligosaccharides would have greater
specificity for a heparin-binding growth factor (Hahnenberger et
al, 1993; Maccarana et al, 1993; Ishihara, 1994; Ishihara et al,
1994), from the clinical standpoint bovine lung heparin oligosac-
charides are attractive anti-growth factor agents, as their structure
encompasses features required for the binding ofHGF (Lyon et al,
1994b) as well as other members ofthe FGF family (Guimond et
al, 1993; Ishihara, 1994). Thus, an inhibitory oligosaccharide
derived from bovine lung heparin may have the capacity to inhibit
at least four growth factors (HGF, personal communication from
M Lyon, JA Deakin andJT Gallagher) that havebeenimplicated in
cancer biology, and we are investigating this.
The majority of data (above and Aviezer et al, 1994) suggest
that tetrasaccharides and disaccharides have a weak inhibitory
effect on the bFGF-FGF receptor interaction and that the optimum
length for bFGF inhibitors is an octasaccharide or hexasaccharide.
In contrast, Ornitz et al (1995) recently reported that certain non-
sulphated heparan disaccharides had the potential to activate
bFGF. The physiological importance ofthis observation is unclear,
since these disaccharides would be found only inside degradative
lysosomes, where they would not have access to the bFGF-FGF
receptor complex. In addition, the data did not show any clear
structure-function relationship.
There are a number of heparan sulphate-dependent growth
factors, including other FGFs, VEGF, HGF and HB-EGF. The
model investigated here serves as a prototype for oligosaccharides
that can act as growth factor inhibitors, and since these growth
factors have been implicated in both cancer cell growth and angio-
genesis (Mustonen and Alitalo, 1995), heparan sulphate and
heparin oligosaccharides hold promise as novel anti-cancer agents.
ABBREVIATIONS
bFGF, basic fibroblast growth factor; CS, chondroitin sulphate;
D+T, DMEM, pyruvate, glutamine, penicillin, streptomycin and
10gg ml-' transferrin; DMEM, Dulbecco's modified Eagle
medium; dp, degree of polymerization; dp6, hexasaccharides;
EGF, epidermal growth factor; GAG, glycosaminoglycans; GlcNS,
N-sulphated glucosamine; GlnNS(6S), N-sulphated glucosamine
6-0-sulphate; HB-EGF, heparin-binding EGF; HGF, hepatocyte
growth factor; HPLC, high-performance liquid chromatography;
HS, heparan sulphate; IdoA(2S), iduronic acid 2-0-sulphate;
LMWH, low-molecular weight heparin; PAPS, phosphoadenosine
phosphosulphate; VEGF, vascular endothelial growth factor.
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